SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: A.J. Mullen who wrote (10201)1/29/2004 1:53:55 PM
From: Biomaven  Read Replies (1) | Respond to of 52153
 
It should be noted that the FDA doesn't like combination drugs at all. Generally you have to demonstrate improvement over each component separately.

A good example of their attitude is POZN - the FDA insisted on full multi-year tox studies for the combo of two already approved drugs even though there was no hint of any drug interaction. (Both of POZN's important drug candidates are combinations of approved drugs).

Peter


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News